FCGR3A F158V alleles frequency differs in multiple myeloma patients from healthy population

被引:1
作者
Constantinides, Michael [1 ,2 ]
Robert, Nicolas [3 ]
Multrier, Caroline [1 ]
Coenon, Lois [1 ]
Campos-Mora, Mauricio [1 ]
Jacquard, Carine [1 ]
Gao, Fei [1 ]
Zemiti, Sara [1 ]
Presumey, Jessy [1 ]
Cartron, Guillaume [2 ]
Moreaux, Jerome [3 ,4 ,5 ]
Villalba, Martin [1 ,6 ]
机构
[1] Univ Montpellier, CHU Montpellier, IRMB, INSERM, Montpellier, France
[2] CHU Montpellier, Dept Clin Hematol, Montpellier, France
[3] CHU Montpellier, Dept Biol Hematol, Montpellier, France
[4] Inst Human Genet, UMR CNRS UM 9002, Montpellier, France
[5] Inst Univ France IUF, Paris, France
[6] Univ Montpellier, IRMB, INSERM, CNRS,CHRU Montpellier, Montpellier, France
来源
ONCOIMMUNOLOGY | 2024年 / 13卷 / 01期
关键词
FCGR3A polymorphism; Fc gamma RIIIa/CD16a; monoclonal gammopathy of undetermined significance (MGUS); multiple myeloma (MM); tumor environment; FC-GAMMA-RIIIA; NATURAL-KILLER-CELLS; POLYMORPHISM INFLUENCES; MONOCLONAL GAMMOPATHY; RECEPTOR EXPRESSION; IIIA-POLYMORPHISM; RITUXIMAB; IGG; IDENTIFICATION; AFFINITY;
D O I
10.1080/2162402X.2024.2388306
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
FCGR3A presents a single nucleotide polymorphism at location 158 (V/F), which affects its binding to the fragment crystallizable (Fc) of antibodies (Abs). Fc gamma RIIIa-158 V allotype has the highest affinity and is associated with a better clinical response to IgG1 monoclonal Abs (mAb) treatment. We compared the allele frequency of FCGR3A-F158V polymorphism in cohorts of patients with B-cell lymphoproliferative disorders, including multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), non-Hodgkin lymphoma (NHL), and B-cell chronic leukemia (B-CLL). FCGR3A-158F homozygous were enriched and tended to be in MM and MGUS patients, respectively; but neither in B-CLL nor in NHL patients. We identified a significantly lower concentration of CD8 T-cells and resting memory CD4 T-cells in MM patients bone marrow with the F/F genotype, associated with an increase in the macrophage percentage. In contrast, natural killer cells increased in V/V homozygous patients. This suggests a deregulation of the immune microenvironment in FCGR3A-F/F homozygous patients. However, we did not observe difference in response following treatment combining chemotherapy associated or not with daratumumab, an IgG1 mAb direct against CD38. Our findings suggest that FCGR3A F158V polymorphism can regulate the immune environment and affect the development of tumor plasma cells.
引用
收藏
页数:9
相关论文
共 47 条
  • [1] Comprehensive characterization of the epigenetic landscape in Multiple Myeloma
    Alaterre, Elina
    Ovejero, Sara
    Herviou, Laurie
    de Boussac, Hugues
    Papadopoulos, Giorgio
    Kulis, Marta
    Boireau, Stephanie
    Robert, Nicolas
    Requirand, Guilhem
    Bruyer, Angelique
    Cartron, Guillaume
    Vincent, Laure
    Martinez, Anne Marie
    Martin-Subero, Jose Ignacio
    Cavalli, Giacomo
    Moreaux, Jerome
    [J]. THERANOSTICS, 2022, 12 (04): : 1715 - 1729
  • [2] RNA-Sequencing-Based Transcriptomic Score with Prognostic and Theranostic Values in Multiple Myeloma
    Alaterre, Elina
    Vikova, Veronika
    Kassambara, Alboukadel
    Bruyer, Angelique
    Robert, Nicolas
    Requirand, Guilhem
    Bret, Caroline
    Herbaux, Charles
    Vincent, Laure
    Cartron, Guillaume
    Elemento, Olivier
    Moreaux, Jerome
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2021, 11 (10):
  • [3] Automated and simplified identification of normal and abnormal plasma cells in Multiple Myeloma by flow cytometry
    Alaterre, Elina
    Raimbault, Sebastien
    Garcia, Jean-Michel
    Reme, Thierry
    Requirand, Guilhem
    Klein, Bernard
    Moreaux, Jerome
    [J]. CYTOMETRY PART B-CLINICAL CYTOMETRY, 2018, 94 (03) : 484 - 492
  • [4] The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus
    Anolik, JH
    Campbell, D
    Felgar, RE
    Young, F
    Sanz, I
    Rosenblatt, J
    Looney, RJ
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (02): : 455 - 459
  • [5] Impact of FcγRIIa-FcγRIIIa Polymorphisms and KRAS Mutations on the Clinical Outcome of Patients With Metastatic Colorectal Cancer Treated With Cetuximab Plus Irinotecan
    Bibeau, Frederic
    Lopez-Crapez, Evelyne
    Di Fiore, Frederic
    Thezenas, Simon
    Ychou, Marc
    Blanchard, France
    Lamy, Aude
    Penault-Llorca, Frederique
    Frebourg, Thierry
    Michel, Pierre
    Sabourin, Jean-Christophe
    Boissiere-Michot, Florence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (07) : 1122 - 1129
  • [6] Specificity and affinity of human Fcγ receptors and their polymorphic variants for human IgG subclasses
    Bruhns, Pierre
    Iannascoli, Bruno
    England, Patrick
    Mancardi, David A.
    Fernandez, Nadine
    Jorieux, Sylvie
    Daeron, Marc
    [J]. BLOOD, 2009, 113 (16) : 3716 - 3725
  • [7] Detection of the FCGR3a polymorphism using a real-time polymerase chain reaction assay
    Burchard, Paul R.
    Malhotra, Saurabh
    Kaur, Prabhjot
    Tsongalis, Gregory J.
    [J]. CANCER GENETICS, 2013, 206 (04) : 130 - 134
  • [8] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene
    Cartron, G
    Dacheux, L
    Salles, G
    Solal-Celigny, P
    Bardos, P
    Colombat, P
    Watier, H
    [J]. BLOOD, 2002, 99 (03) : 754 - 758
  • [9] Distribution of the FcγRIIIa 176 F/V polymorphism amongst healthy chinese, malays and asian indians in singapore
    Chong, K. T.
    Ho, W. F.
    Koo, S. H.
    Thompson, Peter
    Lee, Edmund J. D.
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2007, 63 (03) : 328 - 332
  • [10] From CD16a Biology to Antibody-Dependent Cell-Mediated Cytotoxicity Improvement
    Coenon, Lois
    Villalba, Martin
    [J]. FRONTIERS IN IMMUNOLOGY, 2022, 13